Brief: Hyloris Pharmaceuticals H1 Operating Loss Widens To 3.6 Million Euros

Hyloris Pharmaceuticals SA

06/08/2020 07:33

Aug 6 (Reuters) - HYLORIS PHARMACEUTICALS  HYL.BR :
    * H1 REVENUE EUR 82,000 VS EUR 75,000 YR AGO
    * CASH AND CASH EQUIVALENTS INCREASED TO €66.8 MILLION ON
JUNE 30,
2020 COMPARED TO €0.2 MILLION ON DECEMBER 31, 2019
    * H1 LOSS OF THE PERIOD EUR 3.7 MLN VS LOSS EUR 1.3 MLN YR
AGO
    * H1 OPERATING LOSS EUR 3.6 MLN VS LOSS EUR 1.0 MLN YR AGO
    * HYLORIS CONTINUED TO SUCCESSFULLY DEVELOP ITS PRODUCT
PORTFOLIO
OVER THE FIRST SIX MONTHS OF 2020
    * MANAGEMENT BELIEVES THAT HYLORIS IS WELL POSITIONED FOR
REMAINDER OF 2020 AND BEYOND    
    * ANTICIPATES COMMERCIAL LAUNCH OF SOTALOL IV UNDER NEW
EXTENDED
LABEL IN US
    * ANTICIPATES FIRST EUROPEAN REGULATORY APPROVALS OF
MAXIGESIC® IV
    * ANTICIPATES FDA SUBMISSION FOR MARKET APPROVAL OF
MAXIGESIC IV
AND TRANEXAMIC ACID
    * OPERATIONS WERE NOT MATERIALLY AFFECTED BY COVID-19
PANDEMIC

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE3T1pXN
    
 Further company coverage:  HYL.BR  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))